Portola Pharmaceuticals (PTLA +10.1%) moves up after saying late yesterday that it had entered...


Portola Pharmaceuticals (PTLA +10.1%) moves up after saying late yesterday that it had entered into a clinical collaboration agreement with Daiichi Sankyo (DSNKY.PK) to conduct a Phase 2 study of its investigational Factor Xa inhibitor antidote PRT4445, or andexanet alfa. The study will at several different doses to reverse the anticoagulant effects of Daiichi Sankyo's oral direct Factor Xa inhibitor edoxaban in healthy volunteers.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs